MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Charts
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
HLN stock logo

HLN

Haleon plc

$9.19
-0.03
 (-0.33%)
Exchange:  NYSE
Market Cap:  40.471B
Shares Outstanding:  9.235B
Delayed data
Calculate HLN Intrinsic Value
5-year outlook →
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  HealthcareView sector performance
Industry:  Drug Manufacturers – Specialty & GenericView industry performance
   
CEO:  Brian James McNamara
Full Time Employees:  24535
Address: 
The Heights
Weybridge
SU
KT13 0NY
GB
Website:  https://www.haleon.com
Haleon plc is a significant global entity in the consumer healthcare sector, engaging in the entire process from scientific research and development to the production and worldwide distribution of various wellness goods. The company’s reach extends across North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific region. Its diverse product portfolio encompasses therapeutic solutions for oral care, pain management, respiratory well-being, and digestive health, alongside a comprehensive range of vitamins, minerals, and other dietary supplements. Noteworthy brands within its collection include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. Established in 2021, the company was initially known as DRVW 2022 plc before officially changing its name to Haleon plc in February 2022. It is headquartered in Brentford, United Kingdom.

Click to read more…

Revenue Segmentation

MARKETSnap
MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2025/05/02 — Q1 quarter 2025

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue11,302,00011,233,00011,030,000
Gross Profit6,961,0006,948,0006,987,442.354
EBITDA2,351,0002,514,0002,879,483.522
Operating Income1,996,0002,206,0002,412,000
Net Income1,049,0001,442,0001,630,468.421

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets34,055,00034,315,00032,572,646.510
Total Liabilities17,326,00018,091,00016,117,620.304
Total Stockholders Equity16,606,00016,166,00016,396,129.908
Total Debt9,456,00010,102,0008,593,868.029
Cash and Cash Equivalents1,044,0002,195,0001,321,672.815

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow2,100,0002,301,0002,285,785.663
Capital Expenditure-336,000-250,000-314,943.506
Free Cash Flow1,764,0002,051,0001,970,842.156
Net Income1,111,0001,442,0001,630,468.421
Net Change in Cash383,0001,213,000-769,659.848

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)12,990,783.479Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)13,273,331.936Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)13,124,923.617Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)3,938,068.722Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)4,028,875.913Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)3,981,195.986Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)2,345,247.104Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)2,411,749.539Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)2,376,831.255Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)5,014,361.826Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)5,123,423.778Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)5,066,139.087Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)0.530Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)0.540Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)0.520Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)7Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)2Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
14.354B  ?P/S
 (TTM)
: 
2.79
?Net Income
 (TTM)
: 
1.843B  ?P/E
 (TTM)
: 
19.45
?Enterprise Value
 (TTM)
: 
38.499B  ?EV/FCF
 (TTM)
: 
32.43
?Dividend Yield
 (TTM)
: 
2.07%  ?Payout Ratio
 (TTM)
: 
39%
?ROE
 (TTM)
: 
9.9%  ?ROIC
 (TTM)
: 
6.46%
?Net Debt
 (TTM)
: 
9.865B  ?Debt/Equity
 (TTM)
: 
0.5
?P/B
 (TTM)
: 
1.92  ?Current Ratio
 (TTM)
: 
0.69

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
15.80Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

Strengths (preview)

  • Strong Emerging Market Performance: Haleon demonstrated robust momentum in emerging markets during the Full Year 2024 Earnings Call, contributing significantly to overall revenue growth. This highlights the company’s effective market penetration and brand strength in high-growth regions.
  • Positive Financial Metrics: Key financial results from the 2024 earnings call and income statements indicate consistent revenue and gross profit growth, supported by strategic product innovations. The company’s operating cash flow and free cash flow remain solid, reflecting operational efficiency.
  • Innovation-Driven Growth: The earnings call emphasized Haleon’s focus on product innovation as a key driver of performance, positioning the company to maintain competitive advantage within its industry.
  • Favorable Valuation Metrics: Haleon’s current price-to-earnings ratio (P/E TTM) and forward P/E ratios suggest the stock is reasonably valued compared to industry averages, offering potential stability for investors based on analyst estimates.

Log in with Research Access for Weaknesses, Opportunities, Threats, and the complete SWOT.

Log in to continue

Log in with Full Access for the complete SWOT analysis.

Login — it's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.

[intrinsic_calculator]

Common questions about HLN valuation

Is Haleon plc (HLN) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Haleon plc (HLN) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is HLN a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether HLN trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is HLN’s P/E ratio?

You can see HLN’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for HLN?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is HLN a good long-term investment?

Whether HLN fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

HLN

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

-0.33
MARKETSnap

Trading Metrics:

Open: 9.2   Previous Close: 9.22
Day Low: 9.1   Day High: 9.22
Year Low: 8.65   Year High: 11.28
Price Avg 50: 9.86   Price Avg 200: 9.84
Volume: 10.036M   Average Volume: 10.065M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free

HLN full analysis

12/03/2026

Hey everyone, welcome back to the channel! Today, we’re diving deep into a comprehensive analysis of Haleon, ticker HLN, a major player in the consumer healthcare space. If you’re curious about whether this stock deserves a spot in your portfolio, stick around because we’re breaking down everything from financials to recent performance, and even a SWOT analysis to give you the full picture. Let’s get started! First off, let’s set the stage. Haleon is a company that’s all about everyday…

Open MarketSnap Listen

Log in to continue

Log in to see the full analysis preview and audio links.

Login — it's free

Industry Peers

TICKERCOMPANYMKT CAPP/EFWD P/EROIC
HLHLN logoHLNHaleon plc This stock40.5B19.415.86.5%
TETEVA logoTEVATeva Pharmaceutical Industries Limited43.2B57.718.69.0%
ZTZTS logoZTSZoetis Inc.30.6B12.511.721.6%
TATAK logoTAKTakeda Pharmaceutical Company Limited58.1B50.439.12.4%
VTVTRS logoVTRSViatris Inc.19.2B—6.7-0.2%
ELELAN logoELANElanco Animal Health Incorporated11.6B—22.53.9%
See in Nexus

Relevant news

Haleon plc: Announces Pricing Terms, Expiration and Results of its Cash Tender Offer for outstanding 2027 Notes
19-08-2026 05:00
Haleon plc: Announces Pricing Terms, Expiration and Results of its Cash Tender Offer for outstanding 2027 Notes
Haleon to Accelerate AI-powered Transformation With New Five-year Microsoft Collaboration
01-07-2026 05:00
Haleon to Accelerate AI-powered Transformation With New Five-year Microsoft Collaboration
Haleon Issues Voluntary Nationwide Recall of Gas-X Extra Strength Softgels 125mg, 120 ct. and 72 ct.
04-06-2026 14:32
Haleon Issues Voluntary Nationwide Recall of Gas-X Extra Strength Softgels 125mg, 120 ct. and 72 ct.
Haleon plc (HLN) Presents at 23rd annual dbAccess Global Consumer Conference Transcript
03-06-2026 13:32
Haleon plc (HLN) Presents at 23rd annual dbAccess Global Consumer Conference Transcript
‘For The Assist': Haleon Canada launches national campaign with Canada Soccer to celebrate the small health supports behind Canadian wellbeing
21-05-2026 09:59
‘For The Assist': Haleon Canada launches national campaign with Canada Soccer to celebrate the small health supports behind Canadian wellbeing
Haleon plc (HLN) Q1 2026 Sales/Trading Call Transcript
29-04-2026 09:02
Haleon plc (HLN) Q1 2026 Sales/Trading Call Transcript

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
      • Large Caps
      • Absolute
      • Total Market PE
      • Large Caps
      • Absolute
      • Industry
      • Sector
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Philosophy
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlist & Portfolio Watchlist & Portfolio
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read